Neopharm네오팜
092730 · KOSDAQ · ₩092730 · 네오팜
₩22,100▼ ₩1,250 (5.35%)End-of-day · Oct 26, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 66.3% | 65.3% | 62.4% | 67.3% | 69.1% | 70.8% |
| Operating margin | 21.9% | 21.8% | 20.8% | 26.4% | 26.6% | 24.5% |
| Net margin | 25.4% | 21.1% | 19.2% | 24.1% | 21.3% | 19.0% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +12.3% | +10.8% | +22.8% | +15.2% | −3.7% | — |
| Operating income growth | +12.7% | +16.2% | −3.0% | +14.5% | +4.2% | — |
| Net income growth | +35.1% | +21.9% | −2.2% | +30.4% | +7.9% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 19.0% | 15.0% | 13.6% | 15.5% | 13.3% | 12.9% |
| Return on assets | 13.1% | 13.6% | 12.4% | 14.1% | 12.1% | 11.7% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 12.5% | 11.5% | 8.8% | 10.9% | 9.2% | 10.3% |
| Net debt to equity | −11.2% | −72.9% | −72.3% | −70.9% | −7.6% | −5.3% |
| Current ratio | 752.6% | 838.3% | 1,012.6% | 793.6% | 997.7% | 920.4% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Neopharm / 네오팜 / 092730 / KRX:092730
Source: KRX statistical information